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Abstract  
INTRODUCTION: Ovarian cancer is the cause of a high case-fatality ratio, and most of the cases are diagnosed 
in late stages. 
OBJECTIVES: To determine the histopathological types, age distribution, and ovarian tumour stages among 
diagnosed with ovarian cancer at Al - Amal Tower a multi-referral polyclinic of Radiology & Isotope Center 
Khartoum (RICK), Sudan. 
METHODS: All histopathology reports patients' case from January to June 2015 were reviewed. The cancers 
classified according to federation international of Obstetrics and Gynecology (FIGO). 
RESULTS: There were 127 cases of ovarian cancers. Surface epithelial cancers were the most common 77.7% 
(n = 98), followed by sex cord-stromal cancers 11.23% (n = 14), Germ cell tumor 1.6% (n = 2). Metastatic cancers 
were seen from colon and breast in 6.3% and 3.9 % of cases respectively. Few cases (14%) of ovarian cancers 
were reported before 40 years of age, after the age of 50 is a sharp increase in the incidence of a tumour. The 
mean age at presentation was 52.36 ± 14.210 years, there is mean age of menarche 13.59 ± 2.706 years. Very 
few patients used HRT (1.6%) or had been on ovulation induction treatment (8.7%). Most of patients 39 (30.7%) 
presented in stage IIIC, and stage 1V 32 (25.2%) indicating a poor prognosis. 
CONCLUSION: The incidence of different types of ovarian cancers in the present study is similar to worldwide 
incidence. The surface epithelial tumour is the commonest ovarian cancer, of which serous adenocarcinoma is 
the commonest and most of our patients present in late stages. 
 
 
 
 
Introduction 
 
Ovarian cancer is the second most common 
cause of death from gynecologic tumours in the 
United States [1][2]. Initially, symptoms may be vague 
or not apparent, but they become more noticeable as 
the disease progresses. Early symptoms of ovarian 
cancer include bloating, pelvic nausea pain, and 
abdominal swelling [3]. Peritoneal cavity, lymph 
nodes, lungs, and liver are the most common site for 
metastasis [4]. The risk of ovarian cancer increases 
with ovulation induction treatment, nulliparity, women 
on hormonal replacement therapy, and those begin 
ovulation at a younger age or reach menopause at an 
older age at a higher risk of ovarian cancer [5][6]. 
Factors that decrease the risk of ovarian cancer 
include the use of OCP, tubal ligation, and 
breastfeeding [6]. Genetic inheritances are 
responsible for 10% of cases; the estimated risk for 
women with BRCA1 or BRCA2 is 50% [6]. The most 
common type of ovarian malignancies is epithelial cell 
carcinoma which accounts for 95% of cases. There 
are five main subtypes of epithelial cell carcinoma, of 
which high - grade serous is most common. These 
tumours originate from inclusion cysts in the cells 
overlying the ovaries [5] though some may form at the 
Fallopian tubes [7] [8]. Infrequent types of ovarian 
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cancer include germ cell tumours and sex cord 
stromal tumours [5]. The diagnosis of ovarian cancer 
is confirmed by histopathology examination.  
This study aimed to determine the 
histopathological pattern of ovarian cancer stages, 
and the age distribution in the patients diagnosed at Al 
- Amal Gynecologic Oncology Hospital, Khartoum, 
Sudan. 
 
 
Material and Methods 
 
This is a prospective cross-sectional hospital-
based study conducted at Al-Amal Tower a multi-
referral polyclinic of Radiology & Isotope Center 
Khartoum (RICK) which is the most leading Oncology 
Center in Sudan since founded in 1967. Where over 
6,800 new cancer cases were diagnosed & managed 
in 2014. The study was carried out from January to 
June 2015. The study population composed of 
patients diagnosed as having ovarian cancer. 
Eligibility is limited to the Alamal Oncology Tower. 
 
Data collection tools 
Demographic data were gathered including 
age; residence, menarche and family history of breast, 
ovarian and colonic cancer. History of ovulation 
induction treatment and uses hormonal replacement 
therapy were recorded. Histopathology report of the 
examined specimen was obtained from the histology 
laboratory. 
 
Ethical consideration 
 The study was approved by the Ethics 
Review Committee of the Sudan Medical 
Specialization Board, Council of Obstetrics and 
Gynaecology and AL-amal Ethics Committee. Formal 
consent was taken from each participant written 
consent was taken from each participant.  
 
Data collection 
To ensure completion of questionnaire data 
was collected by a senior registrar in Obstetrics and 
Gynecology. 
 
Statistical analysis 
The statistical package for the social sciences 
(SPSS version 20 for Windows) was used for data 
analyses. The descriptive statistical analyses used 
included the mean, standard deviation, and frequency 
distribution. 
Results 
 
The mean age of the study group was 52.36 ± 
14.210 years (ranged from14 to 95 years). Their mean 
age at menarche was 13.59 ± 2.706 years and a 
mean parity of 4.41 ± 3.396 deliveries. The mean 
menopausal age was 33.85 ± 21.991 years, and the 
parity was 4.41 ± 3.99 deliveries. The majority of 
patients were from the central states of Sudan. Few of 
them had been using combined oral contraceptives, 
ovulation induction treatment and hormonal 
replacement therapy, 7.1%, 8.7%, and 1.6% 
respectively.  
Table 1: Basic characteristics of study population 
Mean maternal age  52.36 ± 14.210 years  
Age of menarche 13.59 ± 2.706 years 
mean parity  2.2756 ±.76301 years 
Oral contraceptive pills users 9 (7.1%) 
Ovulation  induction medications  11 (8.7) 
HRT use  2 (1.6) 
Nulliparous   22 (17.3) 
Multiparous    47 (37) 
Grand multiparous   58( 45.7) 
Data present as number (%). 
 
The family history of ovarian, breast or colonic 
cancer was positive in 11.8% (n = 15) of cases. The 
mean age for endometrioid tumours was 64 ± 4 years, 
while that for mucinous, serous transitional and 
adenosarcoma was similar. The mean age of 
occurrence of Sertoli cell tumours and Clear cell 
tumours was at late reproductive life as shown in 
Table 1 and 2.  
Table 2: The mean age of occurrence of different types of 
ovarian cancer 
Cancer  Age mean ± SD years 
Serous adenocarcinoma 54.2 ± 14 
Mucinous  adenocarcinoma 50 ± 16 
Endometrioid tumours 64 ± 4 
Clear cell tumours 39 ± 3 
Transitional cell tumours 52.4 ± 14.2 
Adenosarcoma 52.3 ± 3 
Granulosa tumours 53.2 ± 6 
Sertoli cell tumours 45.7 ± 3 
 
Bilateral involvement of both ovaries was 
reported in more than half of cases (52%, n = 66), 
followed by the right ovary 27.6 (n = 35) and the left 
ovary 20.5% (n = 2). of all surface epithelial tumours 
77.1% (n = 98), 13.3% (n = 13) were borderline 
tumour. Of all ovarian tumours, serous 
adenocarcinoma was the most common type (44.1%), 
followed by mucinous adenocarcinoma 12.6%, 
detailed of other types are shown in Table 3. The 
second reported an ovarian tumour was sex cord-
stromal tumours which comprised 11.23% of all cases 
detailed are shown in Table 3. Germ cell tumour was 
reported in only 1.6% (n = 2) of cases, while 
metastatic cancer is most commonly seen from the 
colon (6.3%) and only 3.9 % from breasts (Table 3). 
Most of the patients 39 (30.7%) presented in 
stage IIIC, and 32 (25.2%) presented at stage IV, 
while 14 (11.0%) of patients presented in stage IC, 
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and 9 (7.1%) patients presented in stage IIA, and only 
8 (6.3%) patients in stage IB, 7 (5.5%) patients at 
stage IA (Table 4).  
Table 3:  Rate of occurrence of different ovarian malignancies 
among the study population 
Frequency of surface epithelial-stromal 77.2% (98) 
Pathology pattern  Frequency % 
Serous tumours Borderline serous  4 3.1 
serous adenocarcinoma 56 44.1 
Musinous tumours  Borderline mucinous tumor 1 0.8 
mucinous adenocarcinoma 16 12.6 
Endometrioid 
tumours 
endometrioid borderline tumour 4 3.1 
endometrioid adenocarcinoma 3 2.4 
Clear cell tumours Borderline tumours 3 2.4 
clear cell adenocarcinoma 3 2.4 
Transitional cell 
tumours 
Borderline Transitional cell 1 0.8 
Epithelial stromal Adenosarcoma 4 3.1 
Carcinosarcoma ( mixed muellerian 
tumor) 
3 2.4 
Frequency of sex cord-stromal tumours 14 (11.2%) 
Granulosa tumours  12 9.4 
Sertoli cell tumours  2 1.6 
Frequency of germ cell tumours 2 (1.6%) 
Immature Teratoma  1 0.8 
Mixed germ cell 
tumours 
 1 0.8 
Frequency of metastatic cancer 13 (10.4%) 
Colonic appendiceal  8 6.3 
Breast  5 3.9 
 
 
 
Discussion 
 
In the present study, we reported an 
incidence of ovarian epithelial carcinoma of 77.2%. It 
is approximating the 85% incidence rate quoted from 
European countries
 
[8]
 
while the even higher rate of 
incidence (90%) has been reported from United 
States [9]. The lower incidence of ovarian cancer in 
our study can be explained by the fact that black 
women are less likely to develop ovarian cancer 
compared to white women.  
Table 4: Tumors stages at the time of presentation 
Stage Frequency % 
IA 7 5.5 
IB 8 6.3 
IC 14 11.0 
IIA 9 7.1 
IIB 6 4.7 
IIC 6 4.7 
IIIA 3 2.4 
IIIB 3 2.4 
IIIC 39 30.7 
IV 32 25.2 
 
 
Studies demonstrated that white women had 
the highest risk of developing ovarian cancer, followed 
by Hispanic, Asian, black, and American Indian 
women [10]. The variation in the incidence of ovarian 
cancer between nations may be due to other factors 
such as sample size in each study, biosocial 
differences of the population, and genetic and other 
environmental factors.  
In the current study, 11.8% of studied cases 
had a positive family history of ovarian cancer. It was 
reported that positive family history is considered most 
important risk, probably mediated through 
inherited genetic mutation which was found to 
increase the risk by 5 – 10% compared 1.4% risk in 
the general population [11]. In the current study, the 
main age of patients at presentation was 52.36 ± 
14.210 years ranged from 14 to 95 years, and almost 
two-thirds of patients were above 50 years of age, and 
only 14% of cases were < 40 years of age. Similar 
results have been obtained by other researchers. The 
American cancer society reported that ovarian cancer 
is rare in women less than 40 years of age. Typically 
the diseases develop after menopause, and almost 
50%of all ovarian cancers are found in women 63 
years of age or older [12].
 
Similarly, the US 
Surveillance, Epidemiology, and End Results (SEER) 
database reported that ovarian neoplasm is a function 
of age after 50 years [13]. The mean age reported in 
the current study for endometrioid adenocarcinoma of 
the ovary (64 ± 4yrears) is consistent with 60 years of 
age reported by other authors [14].  
The average age of menarche is the study 
group was 13.59 ± 2.706 years. Epidemiologic studies 
have inconsistent reports on associations between 
menarcheal age and ovarian cancer risk. One meta-
analysis concluded that there was inversely 
associated between menarcheal age and the risk of 
ovarian cancer [15]. It is suggested that later 
menarcheal age will result in a decreased incidence of 
ovarian cancer by decreasing a woman’s lifetime 
number of ovulation
. 
 
There is consistent literature that infertility and 
low parity increase the risk of ovarian cancer and 
multiparity and the use of oral contraceptives 
decreases the risk [16]. In the present study showed 
that 16.5% (n = 21) were nulliparous women, 37% (n 
= 47) were multiparous, while the majority 45.7 % (n = 
-58) are grand multiparous women. The use ovulation 
induction medications and hormonal replacement 
therapy were linked to increased risk of ovarian 
cancer and the use of HRT for a shorter duration are 
associated with 20% of ovarian cancer [17]. We 
reported that few of our patients used ovulation 
induction treatment (8.7%) and HRT (1.6%).  
The incidence of endometrioid 
adenocarcinoma of the ovary in the current study was 
5.5% which is less than 10 - 25% reported in the 
literature [11] but consistent with a report from Africa 
countries (4.5%) [18]. The present study, sex - cord 
stroma cell comprises 11.2% of all ovarian neoplasm, 
and the majority were granulosa cell tumors which 
comprise 9.4% of cases; a higher incidence (34.4%) 
was reported by Akakpo from Ghana opposed to a 
comparatively similar (7%) incidence rate from USA 
[19].  
We reported an overall 1.6% incidence of 
germ cell tumours which are mainly immature 
teratoma and mixed germ cell tumour. Previous 
studies reported an incidence of 1.1% and 2.6% from 
Africa [18] and USA [20]. Although the disease is 
rarely reported in older age, the mean age for 
immature teratoma in this study was 52.1 years. 
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In the present study, the incidence of 
secondary metastatic cancer to ovary was 10.4% this 
was mainly from colon (6.3%) and ovary (3.9%). The 
figure is relatively lower than the incidence reported 
by Stewart et al. [21] who analysed 116 patients 
diagnosed with metastatic ovarian cancer at the 
Radboud University Nijmegen Medical Centre; they 
reported a 15% incidence rate. The latter authors 
found that 39% were from the gastrointestinal followed 
by breast in 28% and endometrium in 20% of cases 
[18].  
In the present study, bilateral involvement of 
both ovaries was 52%, while has been reported in 
only 25% of cases [22][23]. What the frequency of 
bilaterality of ovarian neoplasm depend primarily on 
tumour type is involved. Pejovic et al. [24] was the first 
to raise the question whether bilateral ovarian 
carcinoma is a due metastasis from another ovary or it 
occurs as a result of two independent primary 
tumours. Analysis by karyotyping and genomic 
hybridisation concluded that bilaterality occurs by a 
metastatic process [22]. The high occurrence of 
bilateral (52%) ovarian neoplasm in the present study 
could be explained by advanced tumour stages at 
presentation which is an indication poor 5 - year’s 
survival rate.  
In conclusion, the incidence of different types 
of ovarian cancers in the present study is similar to 
worldwide incidence. The surface epithelial tumour is 
the commonest ovarian cancer, of which serous 
adenocarcinoma is the commonest and most of our 
patients present in late stages. The limitations of this 
study are the limited number of cases included and 
being a single centre rather than a multicenter study 
which is more informative. Further study with a large 
number of cases is warranted to investigate the 
predictors of ovarian malignancies among Sudanese 
women. 
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